Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Running

STP938 Dencatistat, a first-in-class, tumour-agnostic, orally available CTPS1 inhibitor to treat gynaecologic tumours

Coordinator
Step Pharma, France
Runs
1 June 2026 to 31 August 2027
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101297026

What the project is doing

In the project's own words, from its summary on CORDIS.

Step Pharma is developing dencatistat (STP938), a first-in-class CTPS1 inhibitor that selectively targets CTPS2-null cancers, where tumour cells rely exclusively on CTPS1 for DNA synthesis. This represents a novel tumour-agnostic precision medicine approach that spares healthy tissue, reduces toxicity, and is suitable for oral administration. The current project focuses on advancing dencatistat in gynaecologic cancers, particularly platinum-resistant/refractory ovarian and endometrial tumours, which remain underserved despite high incidence and poor prognosis.

The proposal will deliver a Phase 1b clinical trial in 10 biomarker-selected endometrial cancer patients to establish safety and early efficacy, using a validated CTPS2-loss assay. This trial follows a Phase 1a dose-escalation study already underway in ovarian cancer. If successful, a Phase 2 study will be launched with two cohorts (40 biomarker-positive, 40 biomarker-negative) to validate the predictive power of CTPS2-loss and support broader solid tumour expansion.

This biomarker-guided strategy will help identify patients most likely to benefit, ensuring cost-efficient clinical development and better outcomes. The EIC grant (€2.5M) will fund critical Phase 1b activities, including patient recruitment, biomarker screening, and regulatory preparation. The requested equity (€10M) will enable Phase 2 execution across ovarian and endometrial cancers. While €37.7M in Series C1 funding has been secured for the ovarian trials, EIC support is essential to unlock the remaining €25M (Series C2) to include the endometrial trial and avoid critical delays in development.

This project will lay the foundation for a European-led gynaecologic oncology franchise, with broader application across CTPS2-null solid tumours.

Topics

Who is involved

OrganisationCityCountryRole
Step PharmaParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI